UBS Group
ZVSA

UBS Group’s ZyVersa Therapeutics ZVSA Stock Holding History

UBS Group’s Portfolio ZVSA Stock Details ZVSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-39,280
Closed -$26.6K – 11044
2025
Q2 		$26.6K Buy
39,280
+10,953
+39% +$7.16K ﹤0.01% 8251
2025
Q1 		$17.8K Buy
28,327
+24,140
+577% +$27.2K ﹤0.01% 8308
2024
Q4 		$4.44K Buy
4,187
+3,754
+867% +$5.92K ﹤0.01% 8756
2024
Q3 		$1.04K Buy
+433
New +$1.39K ﹤0.01% 8737
2024
Q2 		– Sell
-1,991
Closed -$14.9K – 10206
2024
Q1 		$14.9K Buy
1,991
+1,664
+509% +$12.5K ﹤0.01% 7051
2023
Q4 		$2.95K Buy
+327
New +$9.2K ﹤0.01% 8033
2023
Q3 		– Hold
0
– – – 9177
2023
Q2 		– Sell
-9
Closed -$6.33K – 9776
2023
Q1 		$6.33K Buy
+9
New +$6.73K ﹤0.01% 7927

Other funds holding ZVSA

GA
Guerra Advisors Miami, Florida $271M AUM 27.78% 1-Year Est. Return

UBS Group's ZVSA Position: Q3 2025 in Review

UBS Group sold out of ZyVersa Therapeutics (ZVSA) in Q3 2025, closing a stake of 39,280 shares — an estimated $26.6K sold.

UBS Group first reported a position in ZVSA in Q1 2023 and held it in 7 quarters. The position peaked at $26.6K in Q2 2025. 1 fund tracked by Wall St. Rank holds ZVSA as of Q3 2025.

  • UBS Group reported no remaining ZyVersa Therapeutics position as of Q3 2025 after selling out during the quarter.
  • UBS Group sold 39,280 ZyVersa Therapeutics shares in Q3 2025, an estimated $26.6K.
  • UBS Group first reported a position in ZyVersa Therapeutics in Q1 2023 and held it in 7 quarters.
  • UBS Group's ZyVersa Therapeutics position peaked at $26.6K in Q2 2025.
  • 1 fund tracked by Wall St. Rank held ZyVersa Therapeutics as of Q3 2025.

Based on UBS Group's 13F filing for Q3 2025, filed 13 Nov 2025.